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ABSTRACT 
Since Cornea crosslinking (CXL) has been proven to halt progression and biomechanically stabilize keratoconus, we 
hypothesized that CXL of the corneal periphery 3 months prior to corneal transplantation can reduce the incidence of 
recurrent ectasia by strengthening the peripheral corneal tissue and causing apoptosis of diseased peripheral host 
keratocytes. Thus, the aim of this case-report was to propose a novel peripheral CXL technique prior to keratoplasty 
and evaluate its safety. A 22-year-old woman was admitted with advanced right keratoconus and corrected distance 
visual acuities of 20/30 in the right eye and 20/200 in the left eye with a manifest refraction of -3.00D/ -8.00D × 36° 
and -17.00D/ -11.50D × 90°, respectively. The proposed treatment involved crosslinking of peripheral corneal tissue 
(6.5-9.5mm), sparing the central cornea and limbus, three months prior to corneal transplantation as a means of 
biomechanically strengthening the peripheral cornea tissue. This procedure was feasible and safe with repopulation 
of the peripheral cornea with keratocytes, no significant endothelial cell loss and a routine postoperative course 
following CXL and DALK. This method might reduce or eliminate the need for repeat corneal transplantation in 
patients with recurrent ectasia. Further studies are needed to confirm the results. 
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INTRODUCTION
Keratoectasia is a progressive thinning disorder of the 
cornea, which compromises the stromal collagen matrix, 
leading to protrusion as well as alteration of corneal shape 
and often significant degrees of myopia and astigmatism [1]. 
Keratoconus is the most common form of keratoectasia 
with an incidence of 1.3 to 25 per 100,000 and a reported 
prevalence of 50 to 230 cases per 100,000 [2]. There is a 
growing body of evidence that implicates genetic factors in 
the pathogenesis of keratoconus. In keratoconus, total 
corneal collagen content is normal but changes in stromal 
collagen fiber and extracellular matrix components, 
keratocyte morphology and cell-matrix interactions have 
been reported. The above changes lead to lamellar slippage 
and subsequent reduction in corneal stiffness, leading to 
corneal apex protrusion and increased corneal power [3].  
Conservative management of keratoectasia typically 
involves the use of spectacle correction in early disease. 
Contact lens correction in the form of rigid gas permeable 
contact lenses are typically required in more advanced 
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disease and is the treatment of choice for most patients 
with keratoconus.  
However, surgical intervention is indicated in patients with 
advanced disease in whom contact lenses are not able to 
provide sufficient visual rehabilitation or if intolerant to 
contact lenses. For advanced cases of ectasia, corneal 
transplantation preferably with deep anterior lamellar 
keratoplasty (DALK), or alternatively penetrating 
keratoplasty (PK) remains the treatment of choice [4, 5].  
Cornea crosslinking (CXL) is a relatively new treatment of 
keratoectasia which aims to stabilize the ectatic process 
using a combination of ultraviolet-A light and a 
chromophore (Riboflavin). Whilst CXL has been shown to 
reduce the need for the more invasive keratoplasty 
procedure, corneal transplantation is still required in a 
significant proportion of patients with keratoconus, with 
large studies reporting a keratoplasty rate of 11.8% after 8 
years and 18.8% over 20 years [6]. 
There are multiple reports of recurrent ectasia, sporadic 
recurrence of ectatic process in recipients of a corneal 
transplant. Recurrent ectasia has been estimated to occur in 
6-11% of transplants up to two decades or more after 
surgery, based on clinical and histopathological evaluation 
[7]. The mean reported latency of recurrence in these 
patients is approximately 19 years, which is analogous to 
the natural progression of keratoconus [8]. Ultimately, the 
associated thinning and bowing of the peripheral cornea 
leads to significant corneal distortion and uncorrectable 
visual impairment, requiring repeat transplantation for 
visual rehabilitation. 
Recurrent ectasia is frequently bilateral and can recur after 
repeat transplantation. Host factors, rather than donor 
ones, are more responsible for the disorder. A slow 
migration of abnormal host keratocytes into the donor 
corneal button has been suggested as a possible 
pathological mechanism, which has been histologically 
demonstrated in patients undergoing repeat PK [9].  
Since CXL has been proven to halt progression and 
biomechanically stabilize keratoconus [10, 11], we 
hypothesized that CXL of the corneal periphery 3 months 
prior to corneal transplantation can reduce the incidence of 
recurrent ectasia by strengthening the peripheral corneal 
tissue and causing apoptosis of diseased peripheral host 
keratocytes. The intervention possibly prevents complete 
repopulation of the graft host junction with host 
keratocytes and reduces the risk of recurrent ectasia. This 
study aimed to evaluate the safety of such a procedure in a 
patient undergoing keratoplasty.  
METHODS 
Surgical Technique 
The surgical procedure was conducted under aseptic 
conditions. Topical anesthetic drops administered and a 
speculum placed between the eyelids. Using an operating 
microscope and a custom designed ophthalmic well (figure 
1A), 20% ethanol solution was applied to the peripheral 6.5-
9.0 mm corneal zone over 20 seconds and the epithelium 
was thereafter removed using a blunt spatula.  
The CXL procedure started with application of riboflavin 
solution composed of dextran-free riboflavin 0.1% with 
hydroxyl, propyl, methyl and cellulose (Collagex Rapid, 
LightMed, San Clemente, Calif., USA), with 10 minutes of 
corneal soaking. Collagen crosslinking was performed at 
a diameter of 11mm using the LightLink CXL UV-A source 
(LightMed, San Clemente, Calif., USA) system with 3 
minutes of continuous UV-A exposure at 30 mW/cm2 
and a total energy dose of 5.4 J/cm2. 
During UV-A irradiation, the central cornea and corneal 
limbus were protected using a custom designed corneal 
shield (figure 1 B), to avoid central corneal endothelial and 
limbal stem cell damage (figure 2A & 2B). Treated eyes were 
dressed by a silicone–hydrogel soft contact lens (PureVision; 
Bausch+Lomb Inc., Rochester, NY) for 3 days. Ciprofloxacin 
0.3% (Alcon Laboratories Inc., Fort Worth, TX) and 
fluorometholone 0.1% (Santen Pharmaceutical Co, Ltd) eye 
drops 4 times a day were administered for one week and 
one month, respectively.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Med Hypothesis Discov Innov Ophthalmol. 2020; 9(2)  
129 PERIPHERAL CORNEA CROSSLINKING BEFORE DEEP ANTERIOR LAMELLAR KERATOPLASTY 
 
 
 
Figure 1. A. Custom Designed Corneal Well Facilitating Peripheral Corneal Epithelial Debridement and Shielding of the Corneal Limbus.  B. Custom 
Designed Corneal Shield, Protecting the Central Cornea and Limbus From Ultraviolet A (UV-A) Irradiation. 
 
 
Figure 2. A. Intraoperative Image of the Peripheral Cornea Crosslinking (CXL) Procedure With the Corneal Shield. B. Intraoperative Image of the 
Peripheral CXL Procedure Without the Corneal Shield. C. Postoperative Image of the Right Eye 3 Months Following Peripheral CXL. D. Postoperative 
Image of the Right Eye 12 Months After DALK and 15 Months After Peripheral CXL. 
 
RESULTS 
Case report 
A 22-year-old woman was referred with advanced right 
keratoconus and corrected distance visual acuities of 20/30 
in the right eye and 20/200 in the left eye with a manifest 
refraction of -3.00D/ -8.00D × 36° and -17.00D/ -11.50D × 
90°, respectively. Slit lamp examination showed mild cornea 
apical scarring but no signs of previous hydrops. Corneal 
tomography (Pentacam, Oculus, Germany) revealed 
advanced ectasia in the left eye with a thinnest pachymetry 
measurement of 425 μm (figure 3A). Laser scanning in vivo 
confocal microscopy (Heidelberg Retina Tomograph III 
Rostock Corneal Module (HRTIII) (Heidelberg Engineering, 
GmBH, Germany)) of the peripheral cornea revealed a 
normal stromal architecture (figure 4A) and an endothelial 
cell count of 3073 cell/mm2 (figure 5A). The patient did not 
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have any other ocular or medical history, but reported 
excessive eye rubbing. After discussing treatment options, 
risks, benefits and alternatives, the patient consented to 
undergo peripheral CXL followed by corneal transplantation 
as she was contact lens intolerant.  
 
The patient underwent peripheral CXL, three months prior 
to a planned keratoplasty procedure as described above. No 
postoperative complications were encountered and the 
cornea fully re-epithelialized by day 3 following peripheral 
CXL. One month following peripheral CXL, laser scanning in 
vivo confocal microscopy demonstrated a reduction in 
keratocyte density with hyper-reflective cytoplasm of 
remaining keratocytes and extracellular lacunae (figure 4 B) 
as well as a stable endothelial cell count of 3028 cell/mm2 
(figure 5B).   
Three months following peripheral CXL and prior to 
undergoing DALK, the patient’s cornea was clear (figure 2C) 
with no significant change based on corneal tomography 
(figure 3B). Laser scanning in vivo confocal microscopy 
showed keratocyte repopulation and improvement in 
hyper-reflectivity of cytoplasm and extracellular lacunae 
(figure 4 C) as well as an endothelial cell count of 3039 
cell/mm2 (figure 5C).   
The keratoplasty procedure was performed under general 
anesthesia, three months following peripheral CXL. A big 
bubble DALK was completed as described by Anwar [12]. An 
8.25 mm full-thickness donor lenticule was then secured 
over the 8.00mm recipient bed with 16, 10-0 monofilament 
nylon interrupted sutures. Postoperatively, the patient was 
given 2-hourly prednisolone acetate 1% (Predforte, 
Allergan, New Zealand) and 4-hourly chloramphenicol 0.5% 
eye drops (Chlorsig, Aspen Pharma Pty Ltd, Australia). The 
postoperative period was uneventful, with in vivo confocal 
scans performed at 3 months post-DALK confirmed 
adequate repopulation of the graft host junction with 
keratocytes (figure 4 D) and a normal endothelial cell count 
of 3139 cell/mm2 (figure 5D). At 12 months’ postoperative, 
the graft was clear (figure 2D). Uncorrected distance visual 
acuity was 20/40 with a corrected distance visual acuity 
(CDVA( of 20/25 with a manifest refraction of -1.50D/-2.00D 
× 50°. Laser in vivo confocal scans performed 12 months 
following DALK confirmed further repopulation of the graft 
host junction with keratocytes (figure 4E) and an endothelial 
cell count of 3149 cell/mm2 (figure 5E). Corneal tomography 
scans 12 months following surgery demonstrated 3.50D 
keratometric astigmatism (figure 3C). 
The study was approved by the local Health and Disability 
Ethics Committee, a branch of the Ministry of Health in New 
Zealand (NTX/08/08/070AM02). Written informed consent 
was obtained from our patient after fully explaining details 
of the study. The study was performed in accordance with 
the Declaration of Helsinki. 
 
 
 
 
Figure 3. A. Tomography Scans Prior to Peripheral Cornea Crosslinking (CXL). B. Tomography Scan 3 Months Following Peripheral CXL. C. Tomography 
Scan 12 Months Following Deep Anterior Lamellar Keratoplasty (DALK).  
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Figure 4. Laser scanning in vivo confocal microscopy (Heidelberg Retina Tomograph III Rostock Corneal Module (HRTIII) (Heidelberg Engineering, GmBH, 
Germany)) images of superior anterior corneal stroma, 7mm from the corneal apex. A. Prior to peripheral crosslinking, demonstrating the typical 
keratocyte appearance and density in a patient with keratoconus.B. One-month post-peripheral crosslinking, demonstrating the expected appearance 
of a reduction in keratocyte density with hyper-reflective cytoplasm of remaining keratocytes and extracellular lacunae. C. Three months post-
peripheral crosslinking, keratocyte repopulation and improvement in hyper-reflectivity of cytoplasm and extracellular lacunae. D. Three months post- 
Deep Anterior Lamellar Keratoplasty (DALK), early repopulation of keratocytes. E. Twelve months post-DALK, further repopulation of keratocytes. 
 
 
Figure 5. Slit scanning in vivo confocal microscopy Confoscan 4 (Nidek Technologies, Gamagori, Japan) images of superior corneal endothelium, 7mm 
from the corneal apex. A. Prior to peripheral crosslinking, mean cell density was 3073 cells/mm2. B. One-month post-peripheral crosslinking, mean cell 
density was 3028 cells/mm2. C. Three months post-peripheral crosslinking, mean cell density was 3039 cells/mm2.  D. Three months post-DALK, mean 
cell density was 3139 cells/mm2. E. Twelve months post- Deep Anterior Lamellar Keratoplasty (DALK), mean cell density was 3149 cells/mm2.   
Method for cell count: Only cells within the clearest 200 x 200 µm (333 x 333 pixels) region of an image were counted. Cell counts used the “L” method, 
whereby cell borders/cell nuclei crossing the left and inferior borders were counted and those crossing the right and superior borders were omitted. 
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DISCUSSION 
Our case report demonstrates the feasibility and safety 
of a peripheral CXL technique prior to DALK in patients 
with keratoconus. This is a potential new use for the CXL 
procedure, which has previously been shown to stabilize 
the underlying ectatic process in keratoconus with the 
potential to “reverse” the disease as quantified by visual, 
refractive and topographic parameters [1, 13].  
The exact molecular mechanism of crosslinking has yet to 
be fully elucidated, but experimental data suggests that it 
occurs via two mechanisms. In the initial phase of 
crosslinking, the riboflavin molecule is excited to its 
single or triplet state and photosensitized oxidation of 
stromal proteins occurs via its interaction with reactive 
oxygen species in an aerobic environment (Type II 
mechanism). After oxygen supply is depleted by the 
crosslinking process, reactive species of radical ions 
interact with a variety of molecules located in the corneal 
stroma in an anaerobic environment (type I mechanism). 
Production of the above molecules in stroma together 
with photochemical insult provoke wound healing 
response in the cornea, which results in increased 
corneal rigidity in the anterior cornea (200um), modulus 
of elasticity, resistance to enzymatic degradation and 
stretching, with an associated decrease in swelling 
percentage and permeability [1].   
Confocal microscopy studies from early postoperative 
period up to 36 months after treatment have previously 
shown changes in the structure and cellularity of the 
cornea following CXL. Immediately following treatment, 
keratocyte apoptosis, stromal edema and a significant 
reduction in anterior stromal nerve fiber density occur. 
Three to six months following CXL, activated keratocytes 
gradually repopulate the corneal stroma from the 
periphery and some studies suggest that new collagen is 
laid in the stromal matrix [14].  
Recurrent ectasia was initially thought to occur from 
incomplete excision of ectatic tissue during initial 
keratoplasty surgery, but histopathological analysis has 
shown that the ectatic process recurs due to the 
migration of abnormal keratocytes from host to donor 
cornea [15]. The latency period is much shorter in cases 
of DALK (mean of 2-3 years) compared to PK (average 19 
years), proposing that recurrences stem from the 
underlying pathology in non-excised corneal tissue, 
which tends to be more in lamellar surgery [15]. Reverse 
ectasia, whereby a donor cornea with underlying 
keratoconus has been transplanted in a host requiring 
transplantation for reasons other than ectasia has also 
been reported in the literature [16], but this is likely a 
very rare phenomenon.  
Our proposed peripheral CXL technique aims to crosslink 
the peripheral corneal rim, which hosts the donor 
corneal button whilst sparing the typically thin central 
cornea which is usually the barrier for patients being 
eligible for conventional CXL, as a minimum de-
epithelialized corneal thickness of 400 μm is 
recommended to avoid potential irradiation damage to 
the corneal endothelium. However, the corneal 
periphery is thicker than the corneal centre in normal 
individuals (612.5±35.3 μm vs. 551.0±39.4 μm) as well as 
patients with keratoconus (567.6±35.2 μm vs. 492.0±61.7 
μm) [17], which allows for safe peripheral CXL, even in 
those with advanced keratoconus.  
Our modified CXL technique protects the limbal basal 
epithelium and its associated “niche”, housing corneal 
stem cells from the direct effect of UV-A rays or free 
radicals generated during the crosslinking process [18]. 
Also, a metallic shield over the limbal area protects the 
limbal epithelial cells from direct exposure to the 
cytotoxic effects of UV-A radiation. This mechanical 
shielding will not prevent diffusion of free radicals from 
the peripherally irradiated cornea tissue. However, 
diffused free radicals have a short half-life and should not 
have a clinically significant impact on the homeostatic 
function of limbal stem cells [18]. We did not observe any 
clinical evidence of limbal stem cell failure following the 
procedure. Crosslinking the entire corneal periphery is 
probably not required as previous studies have 
demonstrated that whilst the ectatic process is 
pancorneal, pathological changes seen in the corneal 
periphery are less pronounced compared to the centre 
[19]. This is also supported by the observation that the 
difference between normal and keratoconic corneal 
thickness profile becomes less pronounced toward the 
limbus [20].  
We postulate that peripheral CXL procedure three 
months prior to keratoplasty allows for sufficient 
repopulation of host keratocytes to allow for a normal 
wound healing response following keratoplasty. This 
period is however not long enough for total repopulation 
of host cells, which potentially allows for healthy donor 
keratocytes, which have previously been shown to 
survive indefinitely following keratoplasty [21] to 
concurrently repopulate the peripheral cornea and 
create a more normal homeostatic environment and 
physiological balance between collagen production and 
proteolytic breakdown of the extracellular matrix.  
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Further studies are required to fully evaluate the rate at 
which collagen is degraded and resynthesized in the 
cornea, as this would impact the durability of peripheral 
CXL treatment. Some investigators have estimated that 
this process takes 6 to 7 years based on experimental 
data, but the true turnover process of collagen in the 
adult human cornea is currently unknown [22]. Other 
potential benefits of peripheral CXL procedure include 
refractive advantages as enhancing the biomechanical 
rigidity of the graft host junction may protect against 
induction of astigmatism and higher order aberrations 
following surgery by reducing the effect of forces at this 
junction [23]. Reduced keratocyte cell density of the host 
following treatment can also potentially decrease the risk 
of immunological rejection [24]. 
Our study had a number of limitations as it was a single 
case report with a modest follow-up of 12 months. 
Larger cohorts of patients, a longer follow-up period, ex-
vivo histopathological as well as in-vivo biomechanical 
evaluation are required to fully understand the effect of 
peripheral CXL prior to DALK.  
CONCLUSION 
The benefits of developing a successful method of 
preventing recurrent ectasia are great and this 
intervention has the potential to significantly reduce the 
need for repeat keratoplasty. However, a number of 
challenges remain before peripheral CXL can be adopted 
routinely. These include further in vivo safety and 
efficacy studies to ensure that following CXL, 
regenerated peripheral keratocytes are functionally and 
metabolically stable and capable of hosting a donor graft. 
More studies should be performed to examine the cost-
effectiveness of routine peripheral CXL prior to 
widespread adoption of this technique.  
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